- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Vor Biopharma Inc.
Headquarters: Cambridge, MA, United States of America
Website: http://www.vorbiopharma.com
Year Founded: 2016
Status: Public
Industry Sector: HealthTechnology
CEO: Bob Ang, MD, MBA
Number Of Employees: 159
Enterprise Value: $16,167,259
PE Ratio: -0.43
Exchange/Ticker 1: NASDAQ:VOR
Exchange/Ticker 2: N/A
Latest Market Cap: $90,804,904
BioCentury | Apr 23, 2025
Management Tracks
Zealand names former Lilly exec Singh as CSO
Plus: Changes at Halda, Calidi, Creyon, Aurion, Protalix, Theradaptive and Boston Scientific
BioCentury | Mar 6, 2025
Management Tracks
John King named commercial head at Dianthus
Plus: CMO Laura Gault steps down at Sage, and updates from Orbis and Nature’s Toolbox
BioCentury | Jun 14, 2024
Management Tracks
Connect leans into its U.S. profile as it remakes its leadership
Plus: Medivation vet Hung now chair of T-Therapeutics and updates from Voyager and Eyenuk
BioCentury | Jun 10, 2024
Management Tracks
Vor CFO Jorgensen to depart
Plus: Ipsen hires Catllà and updates from ConcertAI and Macomics
BioCentury | Aug 25, 2023
Management Tracks
John Orwin named chairman at Cargo
Plus: Ramzi Benamar joins Elucida as CFO, and updates from Innoviva and Sarfez
BioCentury | Dec 20, 2022
Product Development
Stem cell transplants aim for next level of sophistication
Gene editing stem cell transplants makes targeted myeloid, T cell cancer therapies safer: ASH 2022
BioCentury | Dec 8, 2022
Product Development
Dec. 7 Quick Takes: Strong Enhertu data continue with DESTINY-Breast03 readout at SABCS
Plus: EC calls for Illumina to unwind Grail acquisition and updates from Vor, Paragon’s Apogee, Oncopeptides and more
BioCentury | Oct 12, 2022
Management Tracks
Capstan names Turning Point’s Countouriotis as chair
Plus updates from Vor, Osivax, Alvotech and Roth
BioCentury | Apr 15, 2022
Management Tracks
Sarepta veteran O’Neill becomes CEO at Editas
Plus Slapak retires from Vor, and updates from Harbour, Citius and more
BioCentury | Oct 23, 2021
Discovery & Translation
ESGCT preclinical roundup; plus Generation, Pionyr and more
BioCentury’s roundup of translational news
Items per page:
1 - 10 of 36